Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Files to Raise up to $100M in Potential Stock Offerings

NEW YORK (GenomeWeb News) – Third Wave Technologies said yesterday that it has field a shelf registration with the US Securities and Exchange Commission allowing it to sell up to $100 million in securities.
 
The molecular diagnostics company said it may sell an undetermined number of debt securities or common stock, which includes the rights to purchase preferred stock, and that all of these may be issued by exercising warrants.
 
Third Wave plans to use the proceeds of the sale of the securities, which have not been priced, for working capital, and for corporate purposes that could include R&D spending, capital expenses, and for acquisitions of companies, products, or technologies.
 
The Madison, Wis.-based company said it currently has no plans for any specific acquisitions, but that “opportunities may exist” for expansion through acquisition, alliances, or through other deals.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.